UK MHRA grants marketing authorization for Lytenava (bevacizumab gamma) for the treatment of wet AMD – Outlook Therapeutics
Outlook Therapeutics, Inc. announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for Lytenava (bevacizumab gamma), an ophthalmic formulation of… read more.
